Citations

Clear

3314 citation(s) found for "Do, Alexander".

Surgical Management of Thoracolumbar Burst Fractures
Morrissey, Patrick B. , Shafi, Karim , Wagner, Scott C. , Butler, Joseph S. , Kaye, I. David , Sebastian, Arjun S. , Schroeder, Gregory D. , Kepler, Christopher K., Aarabi, Bizhan , Öner, Fetullah Cumhur, Kepler, Christopher K. , Vaccaro, Alexander R.

Mayo Clinic

Clinical Spine Surgery | July 13, 2020 | Volume: 34 | Issue: 1 | Pages: 4-13

10.1097/bsd.0000000000001038 | PMID 32657842 Get It

The management of thoracolumbar burst fractures is controversial with no universally accepted treatment algorithm. Several classification and scoring systems have been developed to assist in surgical decision-making. The most widely accepted are the Thoracolumbar Injury Classification and Severity Score (TLICS) and AOSpine Thoracolumbar Injury Classification Score (TL AOSIS) with both systems designed to provide a simple objective scoring criteria to guide the surgical or nonsurgical management of complex injury patterns. When used in the evaluation and treatment of thoracolumbar burst fractures, both of these systems result in safe and consistent patient care. However, there are important differences between the 2 systems, specifically in the evaluation of the complete burst fractures (AOSIS A4) and patients with transient neurological deficits (AOSIS N1). In these circumstances, the AOSpine system may more accurately capture and characterize injury severity, providing the most refined guidance for optimal treatment. With respect to surgical approach, these systems provide a framework for decision-making based on patient neurology and the status of the posterior tension band. Here we propose an operative treatment algorithm based on these fracture characteristics as well as the level of injury.
Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Annibali, Daniela , Ashton, Katie A. , Auer, Paul L. , Beckmann, Matthias W. , Black, Amanda , Brinton, Louise A. , Buchanan, Daniel D. , Chen, Chu , Chen, Maxine , Cheng, Timothy, Crous‐Bou, Marta , Vivo, Immaculata De , Dörk, Thilo , Dowdy, Sean C. , Easton, Douglas F. , Ekici, Arif B. , Fasching, Peter A. , García‐Closas, Montserrat , Gaudet, Mia M. , Goode, Ellen L. , Gorman, Maggie, Haiman, Christopher A. , Hankinson, Susan E. , Hein, Alexander , Hillemanns, Peter , Hodgson, Shirley, Høivik, Erling A. , Holliday, Elizabeth , Hunter, David J., Lambrechts, Diether , Liang, Xiaolin , Lindblom, Annika , Lissowska, Jolanta , Magliocco, Anthony M., Martin, Lynn , McEvoy, Mark , Mints, Miriam, Nassir, Rami , Otton, Geoffrey, Palles, Claire , Pooler, Loreall , Proietto, Tony, Rübner, Matthias, Runnebaum, Ingo B. , Sacerdote, Carlotta , Sarto, Gloria E., Scott, Rodney J. , Shah, Mitul , Sheng, Xin , Tomlinson, Ian , Trovik, Jone , Wang, Zhaoming , Wentzensen, Nicolas , Xia, Lucy , Webb, Penelope M. , Thompson, Deborah J. , Glubb, Dylan M., O’Mara, Tracy A. , Lambrechts, Diether , Buchanan, Daniel D , Chen, Chu , De Vivo, Immaculata , Dörk, Thilo , Fasching, Peter A , Friedenreich, Christine M , Gaudet, Mia M , Goode, Ellen L , Lu, Lingeng , Sacerdote, Carlotta , Shu, Xiao-Ou , Wang, Zhaoming , Wentzensen, Nicolas , Xiang, Yong‐Bing , Yu, Herbert , Spurdle, Amanda B , O'Mara, Tracy A , Lambrechts, Diether , Webb, Penelope M , Hein, Alexander , Hillemanns, Peter , Lissowska, Jolanta , Lambrechts, Diether , García-Closas, Montserrat , Ekici, Arif B , Nassir, Rami , Palles, Claire , Lindblom, Annika , Kho, Pik Fang , Amant, Frédéric , Attia, John , Chanock, Stephen Jacob , Cook, Linda S. , Czene, Kamila , Dennis, Joe , Dunning, Alison M. , Dürst, Matthias , Fridley, Brooke L. , Giles, Graham G. , Hall, Per N , Hankinson, Susan E. , Jones, Angela, Kraft, Peter , Krakstad, Camilla , Marchand, Loı̈c Le , Long, Jirong , Milne, Roger L. , Mints, Miriam , Rebbeck, Timothy R. , Renner, Stefan P. , Risch, Harvey A. , Schumacher, Fredrick R. , Setiawan, Veronica Wendy , Shu, Xiao‐Ou , Southey, Melissa C. , Tham, Emma , Turman, Constance , Tyrer, Jonathan P. , Berg, David Van Den , Yang, Hannah , Yu, Kai , Zheng, Wei , Spurdle, Amanda B.

Mayo Clinic

International Journal of Cancer | July 13, 2020 | Volume: 148 | Issue: 2 | Pages: 307-319

10.1002/ijc.33206 | PMID 32851660 Get It

Abstract Blood lipids have been associated with the development of a range of cancers, including breast, lung and colorectal cancer. For endometrial cancer, observational studies have reported inconsistent associations between blood lipids and cancer risk. To reduce biases from unmeasured confounding, we performed a bidirectional, two‐sample Mendelian randomization analysis to investigate the relationship between levels of three blood lipids (low‐density lipoprotein [LDL] and high‐density lipoprotein [HDL] cholesterol, and triglycerides) and endometrial cancer risk. Genetic variants associated with each of these blood lipid levels ( P < 5 × 10 −8 ) were identified as instrumental variables, and assessed using genome‐wide association study data from the Endometrial Cancer Association Consortium (12 906 cases and 108 979 controls) and the Global Lipids Genetic Consortium (n = 188 578). Mendelian randomization analyses found genetically raised LDL cholesterol levels to be associated with lower risks of endometrial cancer of all histologies combined, and of endometrioid and non‐endometrioid subtypes. Conversely, higher genetically predicted HDL cholesterol levels were associated with increased risk of non‐endometrioid endometrial cancer. After accounting for the potential confounding role of obesity (as measured by genetic variants associated with body mass index), the association between genetically predicted increased LDL cholesterol levels and lower endometrial cancer risk remained significant, especially for non‐endometrioid endometrial cancer. There was no evidence to support a role for triglycerides in endometrial cancer development. Our study supports a role for LDL and HDL cholesterol in the development of non‐endometrioid endometrial cancer. Further studies are required to understand the mechanisms underlying these findings.
Medication use and polypharmacy in patients referred to a tertiary gastroenterology practice
Chris-Olaiya, Abimbola , Palmer, William C. , Lacy, Brian E. , Chirilă, Răzvan M. , Nikpour, Naveed, McLeod, Ethan, Ryan, Taylor, Maillis, Alexander , Vargas, Emily , Bouras, Ernest P., Stancampiano, Fernando, Lacy, Brian, Chirilă, Răzvan , Maillis, Alex, Bouras, Ernest, Stancampiano, Fernando F. , Heckman, Michael G.

Mayo Clinic

Romanian Journal of Internal Medicine | July 10, 2020 | Volume: 58 | Issue: 4 | Pages: 228-232

10.2478/rjim-2020-0016 | PMID 32543459 Get It

Abstract Introduction. Commonly prescribed medications are associated with various gastrointestinal (GI) side effects but few data are available on prescription medication use and polypharmacy in a gastroenterology outpatient practice. We aimed to examine the prevalence of polypharmacy, defined as the simultaneous use of 5 or more medications. Methods. A descriptive correlational study of consecutive outpatient consultations in 988 patients referred to a tertiary gastroenterology practice. Main outcome measurements were frequency of prescription medication use and polypharmacy. Results. The most common GI symptoms were abdominal pain (72%), nausea (57%), and constipation (53%). The frequency of polypharmacy was 10%. Eighty percent of patients took at least one medication and 60% took two or more. The most frequently used medication classes were proton pump inhibitors (43%), followed by benzodiazepines (30%), selective serotonin-reuptake or norepinephrine-reuptake inhibitors (28%), non-steroidal anti-inflammatory drugs (27%), and opioids (21%). Conclusion. There was a higher use of prescription medicine including antidepressants, and a lower frequency of polypharmacy in our study cohort compared to the general population. The use of medications may have contributed to the symptoms leading to our study’s population GI consultation.
Late-life Physical Exercise, Neuropsychiatric Symptoms And The Risk Of Incident Mild Cognitive Impairment
Syrjanen, Jeremy A. , Vassilaki, Maria , Petersen, Ronald C. , Krell‐Roesch, Janina , Wöll, Alexander , Kremers, Walter K. , Machulda, Mary M. , Mielke, Michelle M. , Knopman, David S. , Geda, Yonas E.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 9, 2020 | Volume: 52 | Issue: 7S | Pages: 339-340

10.1249/01.mss.0000677440.85436.77 Get It

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms
Mi, Xiaoli , North, Khrystyna , Binder, Moritz , Penson, Alexander , Knorr, Katherine , Haddadin, Michael , Liu, Bo , Pangallo, Joseph , Benbarche, Salima , Wiseman, Daniel H. , Tefferi, Ayalew , Patnaik, Mrinal M. , Bradley, Robert K. , Binder, Moritz , Wiseman, Daniel H , Taylor, Justin , Lasho, Terra L. , Halene, Stephanie , Liang, Yang , Abdel‐Wahab, Omar

Mayo Clinic

Blood | July 8, 2020 | Volume: 136 | Issue: 13 | Pages: 1477-1486

10.1182/blood.2020006868 | PMID 32640014 Get It

Abstract Large-scale sequencing studies of hematologic malignancies have revealed notable epistasis among high-frequency mutations. One of the most striking examples of epistasis occurs for mutations in RNA splicing factors. These lesions are among the most common alterations in myeloid neoplasms and generally occur in a mutually exclusive manner, a finding attributed to their synthetic lethal interactions and/or convergent effects. Curiously, however, patients with multiple-concomitant splicing factor mutations have been observed, challenging our understanding of one of the most common examples of epistasis in hematologic malignancies. In this study, we performed bulk and single-cell analyses of patients with myeloid malignancy who were harboring ≥2 splicing factor mutations, to understand the frequency and basis for the coexistence of these mutations. Although mutations in splicing factors were strongly mutually exclusive across 4231 patients (q &lt; .001), 0.85% harbored 2 concomitant bona fide splicing factor mutations, ∼50% of which were present in the same individual cells. However, the distribution of mutations in patients with double mutations deviated from that in those with single mutations, with selection against the most common alleles, SF3B1K700E and SRSF2P95H/L/R, and selection for less common alleles, such as SF3B1 non-K700E mutations, rare amino acid substitutions at SRSF2P95, and combined U2AF1S34/Q157 mutations. SF3B1 and SRSF2 alleles enriched in those with double-mutations had reduced effects on RNA splicing and/or binding compared with the most common alleles. Moreover, dual U2AF1 mutations occurred in cis with preservation of the wild-type allele. These data highlight allele-specific differences as critical in regulating the molecular effects of splicing factor mutations as well as their cooccurrences/exclusivities with one another.
Expression of Nras Q61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice
Wen, Zhi , Rajagopalan, Adhithi , Flietner, Evan, Yun, Grant, Chesi, Marta , Furumo, Quinlan, Burns, Robert T., Papadas, Athanasios , Ranheim, Erik A. , Pagenkopf, Adam , Morrow, Zachary , Finn, Remington, Zhou, Yun , Li, Shuyi , Jensen, Jeffrey L. , Yu, Mei , Cicala, Alexander , Menting, James, Mitsiades, Constantine S. , Bergsagel, P. Leif , Wang, Demin , Asimakopoulos, Fotis , Zhang, Jing , Bergsagel, P. Leif , Wang, Demin , Burns, Robert T., You, Xiaona , Yu, Mei, Callander, Natalie S.

Mayo Clinic

Blood | July 8, 2020 | Volume: 137 | Issue: 1 | Pages: 61-74

10.1182/blood.2020007156 | PMID 32640012 Get It

Abstract NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and correlate with poor patient outcomes. Thus, we generated a novel MM model by conditionally activating expression of endogenous NrasQ61R and an MYC transgene in germinal center (GC) B cells (VQ mice). VQ mice developed a highly malignant MM characterized by a high proliferation index, hyperactivation of extracellular signal-regulated kinase and AKT signaling, impaired hematopoiesis, widespread extramedullary disease, bone lesions, kidney abnormalities, preserved programmed cell death protein 1 and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain immune-checkpoint pathways, and expression of human high-risk MM gene signatures. VQ MM mice recapitulate most of the biological and clinical features of human advanced/high-risk MM. These MM phenotypes are serially transplantable in syngeneic recipients. Two MM cell lines were also derived to facilitate future genetic manipulations. Combination therapies based on MEK inhibition significantly prolonged the survival of VQ mice with advanced-stage MM. Our study provides a strong rationale to develop MEK inhibition–based therapies for treating advanced/relapsed MM.
Fibrillary Glomerulonephritis and DnaJ Homolog Subfamily B Member 9 (DNAJB9)
Klomjit, Nattawat , Alexander, Mariam P., Zand, Ladan , Alexander, Mariam Priya, Klomjit, Nattawat

Mayo Clinic

Kidney360 | July 8, 2020 | Volume: 1 | Issue: 9 | Pages: 1002-1013

10.34067/kid.0002532020 | PMID 35369552 Get It

Fibrillary GN (FGN) is a rare glomerular disease that is diagnosed based on the presence of fibrils in glomeruli. The fibrils are typically noncongophilic, randomly oriented, and measure 12–24 nm. Traditionally, electron microscopy (EM) has been an important tool to aid in the diagnosis of FGN by identifying the fibrils and to distinguish it from other entities that could mimic FGN. However, recently DnaJ homolog subfamily B member 9 (DNAJB9) has emerged as both a specific and sensitive biomarker in patients with FGN. It allows prompt diagnosis and alleviates reliance on EM. DNAJB9 is a cochaperone of heat shock protein 70 and is involved in endoplasmic reticulum protein-folding pathways. But its role in the pathogenesis of FGN remains elusive. DNAJB9 may act as a putative antigen or alternatively it may secondarily bind to misfolded IgG in the glomeruli. These hypotheses need future studies to elucidate the role of DNAJB9 in the pathogenesis of FGN. The treatment regimen for FGN has been limited due to paucity of studies. Most patients receive combination immunosuppressive regimens. Rituximab has been studied the most in FGN and it may delay disease progression. Prognosis of FGN remains poor and 50% require dialysis within 2 years of diagnosis. Despite its poor prognosis in native kidneys, the rate of recurrence post-transplantation is low (20%) and patient as well as allograft outcomes are similar to patients without FGN.
Evaluation of Epidemiological Factors to Determine If There Are Predictors of Lymphangiolieomyomatosis and Elevated Vascular Endothelial Growth Factor-D Levels Among Patients
Lewis, Kathleen, Heckman, Alexander , Patel, Neema , Lewis, K., Helgeson, Scott A. , Burger, Charles D. , Patel, N.

Mayo Clinic

C38. RARE LUNG DISEASES | July 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: A4969-A4969

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4969 Get It

A Multi-Disciplinary Quality Improvement Intervention Focusing on Patient-Driven Goals for Chronically Ill High-Risk Hospitalized Patients
Dempsey, Tyler, Pennington, Kelly M. , Vu, Alexander , Clain, J, Scrodin, M. Dulohery, Vu, A.

Mayo Clinic

B22. PALLIATIVE AND END-OF-LIFE CARE IN SERIOUS ILLNESS | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2818-A2818

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2818 Get It

Egr2-guided histone H2B monoubiquitination is required for peripheral nervous system myelination
Wüst, Hannah M. , Wegener, Amélie , Fröb, Franziska , Hartwig, Anna C., Kari, Vijayalakshmi, Schimmel, Margit, Tamm, Ernst R. , Johnsen, Steven A. , Wegner, Michael , Sock, Elisabeth , Johnsen, Steven A , Wegwitz, Florian

Mayo Clinic

Nucleic Acids Research | July 7, 2020 | Volume: 48 | Issue: 16 | Pages: 8959-8976

10.1093/nar/gkaa606 | PMID 32672815 Get It

AbstractSchwann cells are the nerve ensheathing cells of the peripheral nervous system. Absence, loss and malfunction of Schwann cells or their myelin sheaths lead to peripheral neuropathies such as Charcot-Marie-Tooth disease in humans. During Schwann cell development and myelination chromatin is dramatically modified. However, impact and functional relevance of these modifications are poorly understood. Here, we analyzed histone H2B monoubiquitination as one such chromatin modification by conditionally deleting the Rnf40 subunit of the responsible E3 ligase in mice. Rnf40-deficient Schwann cells were arrested immediately before myelination or generated abnormally thin, unstable myelin, resulting in a peripheral neuropathy characterized by hypomyelination and progressive axonal degeneration. By combining sequencing techniques with functional studies we show that H2B monoubiquitination does not influence global gene expression patterns, but instead ensures selective high expression of myelin and lipid biosynthesis genes and proper repression of immaturity genes. This requires the specific recruitment of the Rnf40-containing E3 ligase by Egr2, the central transcriptional regulator of peripheral myelination, to its target genes. Our study identifies histone ubiquitination as essential for Schwann cell myelination and unravels new disease-relevant links between chromatin modifications and transcription factors in the underlying regulatory network.